Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl Sells 6,250 Shares

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl sold 6,250 shares of Enliven Therapeutics stock in a transaction on Monday, October 28th. The shares were sold at an average price of $28.56, for a total value of $178,500.00. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Benjamin Hohl also recently made the following trade(s):

• On Friday, October 18th, Benjamin Hohl sold 814 shares of Enliven Therapeutics stock. The shares were sold at an average price of $30.00, for a total value of $24,420.00.
• On Friday, October 4th, Benjamin Hohl sold 10,218 shares of Enliven Therapeutics stock. The shares were sold at an average price of $27.51, for a total value of $281,097.18.
• On Monday, October 7th, Benjamin Hohl sold 1,270 shares of Enliven Therapeutics stock. The stock was sold at an average price of $27.51, for a total value of $34,937.70.
• On Friday, September 27th, Benjamin Hohl sold 4,250 shares of Enliven Therapeutics stock. The stock was sold at an average price of $24.27, for a total value of $103,147.50.
• On Monday, September 30th, Benjamin Hohl sold 2,000 shares of Enliven Therapeutics stock. The stock was sold at an average price of $25.33, for a total value of $50,660.00.
• On Tuesday, August 27th, Benjamin Hohl sold 4,250 shares of Enliven Therapeutics stock. The stock was sold at an average price of $22.54, for a total value of $95,795.00.

Enliven Therapeutics Price Performance

Shares of NASDAQ ELVN traded down $0.13 during trading hours on Wednesday, hitting $28.39. 135,036 shares of the company’s stock were exchanged, compared to its average volume of 258,436. Enliven Therapeutics, Inc. has a 1-year low of $9.80 and a 1-year high of $30.03. The stock has a market capitalization of $1.34 billion, a price-to-earnings ratio of -14.87 and a beta of 1.10. The company’s 50-day moving average price is $24.95 and its 200-day moving average price is $23.13.

Enliven Therapeutics (NASDAQ:ELVN) last posted its quarterly earnings data on Tuesday, August 13th. The company reported ($0.41) earnings per share for the quarter, topping the consensus estimate of ($0.58) by $0.17. On average, research analysts expect that Enliven Therapeutics, Inc. will post -1.98 earnings per share for the current year.

Hedge Funds Weigh In On Enliven Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in ELVN. EntryPoint Capital LLC bought a new position in Enliven Therapeutics during the first quarter valued at about $167,000. Baker BROS. Advisors LP bought a new position in Enliven Therapeutics during the first quarter valued at about $2,020,000. Blackstone Inc. bought a new position in Enliven Therapeutics during the first quarter valued at about $443,000. Janus Henderson Group PLC grew its stake in shares of Enliven Therapeutics by 74.8% in the 1st quarter. Janus Henderson Group PLC now owns 713,911 shares of the company’s stock valued at $12,604,000 after purchasing an additional 305,397 shares during the period. Finally, Bank of New York Mellon Corp grew its stake in shares of Enliven Therapeutics by 49.2% in the 2nd quarter. Bank of New York Mellon Corp now owns 114,109 shares of the company’s stock valued at $2,667,000 after purchasing an additional 37,632 shares during the period. 95.08% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $37.00 price target on shares of Enliven Therapeutics in a research report on Tuesday, October 1st.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.